PRIOTHERA
Priothera is a clinical-stage company developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies. We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in these patients.
PRIOTHERA
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2020-01-01
Address:
Dublin, Dublin, Ireland
Country:
Ireland
Website Url:
http://www.priothera.com
Total Employee:
11+
Status:
Active
Total Funding:
49 M EUR
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Global Site Tag Mobile Non Scaleable Content
Similar Organizations
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
KayoThera
KayoThera develops therapeutics used to cure late-stage and metastatic cancers.
Pipeline Therapeutics
Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.
Plexium
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Advisors List
Board_member
2020-10-01
Board_member
2020-10-01
Board_member
2020-10-01
Board_member
2020-10-01
Current Employees Featured
Dhaval Patel Founder & Director @ Priothera
Founder & Director
2020-10-01
Elisabeth Kueenburg Chief Medical Officer @ Priothera
Chief Medical Officer
2021-11-01
Brice R. Suire Chief Financial Officer @ Priothera
Chief Financial Officer
2020-10-01
Florent Gros CEO & Founder @ Priothera
CEO & Founder
2020-01-01
Founder
Investors List
Bpifrance
Bpifrance investment in Debt Financing - Priothera
European Investment Bank
European Investment Bank investment in Debt Financing - Priothera
Fountain Healthcare Partners
Fountain Healthcare Partners investment in Series A - Priothera
Earlybird Venture Capital
Earlybird Venture Capital investment in Series A - Priothera
Tekla Capital Management
Tekla Capital Management investment in Series A - Priothera
HealthCap
HealthCap investment in Series A - Priothera
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-25 | Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer |
Official Site Inspections
http://www.priothera.com Semrush global rank: 6.66 M Semrush visits lastest month: 1.05 K
- Host name: 217.194.223.243
- IP address: 217.194.223.243
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "Priothera"
Priothera | Improving patient’s lives by delivering an innovative ...
Priothera SAS 57 Avenue Général de Gaulle 68300 Saint-Louis, France. Priothera Ltd 88 Harcourt Street, Dublin 2, D02 DK18, Ireland ...See details»
Our Leadership Team | Priothera
Florent Gros is CEO and Co-Founder of Priothera. He has held various leadership positions in venture, intellectual property and transaction matters at Nestlé, Pasteur Merieux Connaught …See details»
Priothera - Crunchbase Company Profile & Funding
Priothera is a clinical-stage company developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies. We are dedicated to improving the lives …See details»
Leadership Team | Priothera
Priothera SAS 57 Avenue Général de Gaulle 68300 Saint-Louis, France. Priothera Ltd 88 Harcourt Street, Dublin 2, D02 DK18, Ireland ...See details»
Priothera - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Priothera . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 4. ... Priothera has 4 board …See details»
Priothera - The Org
Priothera is developing the orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies. Industries. Biotechnology, Health Care +1. Headquarters. …See details»
Priothera - Funding, Financials, Valuation & Investors - Crunchbase
Priothera is developing the orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies. Search Crunchbase. ... How much funding has this organization …See details»
Priothera - VentureRadar
"Priothera is leading the way in developing orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. S1P receptor modulators have shown to …See details»
Priothera - Overview, News & Competitors | ZoomInfo.com
Priothera - Positive mocravimod Phase 1b clinical data published in Transplantation and Cellular Therapy Mocravimod is safe and well-tolerated in allogeneic hematopoietic cell transplantation …See details»
Priothera Company Profile - Office Locations, Competitors ... - Craft
Priothera is a company that develops receptor modulators intended to improve the lives of patients suffering from hematological malignancies. Its receptor modulators reduce the egress …See details»
Priothera 2025 Company Profile: Valuation, Funding
Priothera General Information Description. Developer of receptor modulators intended to improve the lives of patients suffering from haematological malignancies. The company's modulators reduce the egress of T cell subsets …See details»
In the news | Priothera
PRIOTHERA révolutionne le standard des soins dans les thérapies cellulaires en hémato-oncologie Jan 23, 2025 Nous avons fondé Priothera en 2020 autour d’une équipe d’experts …See details»
Priothera SAS: Role of a Promising Molecule in Adding Years to Life
Priothera is a clinical-stage pharma company developing Mocravimod (KRP203), a non-immunosuppressive molecule for the treatment of Acute Myeloid Leukemia and potentially …See details»
Chief Business Officer & Founder at Priothera - The Org
Chief Business Officer & Founder at Priothera. ... Philippe returned to Japan in 2014 to lead and reshape the Novartis Japanese BD&L organization. In 2017, Philippe joined the Basel BD&L …See details»
Press Center | Priothera
Get an overview of Priothera’s recent news articles, and keep up-to-date with our ongoing work and results. If you are a professional member of the media and would like to find out more …See details»
EUROAPI and Priothera enter into CDMO collaboration to advance …
Jun 18, 2024 Priothera is headquartered in Dublin, Ireland, and has a subsidiary in Saint-Louis (Haut-Rhin), France. As part of this collaboration, EUROAPI will develop and industrialize the …See details»
Press Release EUROAPI and Priothera enter into CDMO …
Jun 18, 2024 Development and Manufacturing Organization (CDMO) activity. This project will be carried out at EUROAPI’s site, Budapestits center of excellence for complex ... Priothera was …See details»
Press Release - Priothera
Dec 2, 2024 Priothera is headquartered in Dublin, Ireland, and has a subsidiary in Saint-Louis (Haut-Rhin), France. As part of this collaboration, EUROAPI will develop and industrialize the …See details»
Priothera – US FDA grants Orphan Drug Designation to
Nov 27, 2023 Mocravimod is the only S1P receptor modulator being developed as an adjunctive and maintenance treatment for blood cancers Mocravimod is being investigated in a global …See details»
Our Pipeline - Priothera
At Priothera, we are relentless in our pursuit of therapies that will help patients around the world. Transforming Cancer Care Through Innovation and Commitment. Priothera is building a …See details»